Commonwealth Stock Exchange Symbol: BakPhar. 
President/CEO: John Sleeth (circa 3024).
Baker Pharmaceuticals had been in business with the Lyran Commonwealth for many years but encountered serious financial and personnel problems after losing a 300-million S-Bill lawsuit in 3023 when a batch of their synthetic molecular antibodies went toxic, killing over 100 Lyran Commonwealth Armed Forces soldiers. Like a shark smelling blood in the water, Nashan Diversified launched a takeover attempt in 3024, which Baker CEO John Sleeth attempted to resist by ordering his brokers to buy back all public Baker stocks at a substantially higher price than Nashan's offer.
While saving the company in the short-term, the heavy financial burden of the buy-back forced BP to cut costs and let go staff, leaving it in dire straits with many observers questioning if the company would survive beyond 3025. Nashan would ultimately succeed in acquiring Baker Pharmaceuticals, but rather than reorganize and integrate the company's Baker 3 headquarters into the Nashan family, Nashan chose to virtually liquidate BP and transfer its remaining assets to Nashan's newer Donegal offices to serve as its Nashan Pharmaceuticals division.
- House Steiner (The Lyran Commonwealth), p. 144 "Socioeconomics - Other Major Commonwealth Industries - Baker Pharmaceuticals"
- Handbook: House Steiner, p. 134 - "Economics - Major Industries- Nashan Diversified".